American Renal Associates Holdings Inc. (NYSE:ARA) received a $24.00 price objective from analysts at SunTrust Banks Inc. in a report released on Thursday. The firm currently has a a “buy” rating on the stock. SunTrust Banks Inc.’s target price would indicate a potential upside of 32.60% from the company’s previous close.

A number of other brokerages have also recently issued reports on ARA. Leerink Swann reiterated an “outperform” rating on shares of American Renal Associates Holdings in a research note on Sunday, August 21st. Barclays PLC reiterated a “buy” rating and issued a $31.00 price target on shares of American Renal Associates Holdings in a research note on Thursday, August 18th. Zacks Investment Research upgraded shares of American Renal Associates Holdings from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research note on Thursday, August 11th. Bank of America Corp. reiterated a “buy” rating and issued a $35.00 price target on shares of American Renal Associates Holdings in a research note on Monday, August 22nd. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of American Renal Associates Holdings in a research note on Sunday, September 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $29.50.

Analyst Recommendations for American Renal Associates Holdings (NYSE:ARA)

Shares of American Renal Associates Holdings (NYSE:ARA) traded down 1.38% during trading on Thursday, reaching $17.85. 238,780 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $19.49 and a 200 day moving average price of $24.38. The firm’s market cap is $550.99 million. American Renal Associates Holdings has a 12 month low of $17.43 and a 12 month high of $29.65.

American Renal Associates Holdings (NYSE:ARA) last announced its earnings results on Tuesday, August 9th. The company reported ($0.75) EPS for the quarter. The firm had revenue of $185.60 million for the quarter, compared to analysts’ expectations of $161.50 million. On average, analysts forecast that American Renal Associates Holdings will post $0.95 EPS for the current year.

A number of institutional investors have recently modified their holdings of the company. Acrospire Investment Management LLC acquired a new position in shares of American Renal Associates Holdings during the second quarter worth $130,000. American International Group Inc. acquired a new position in shares of American Renal Associates Holdings during the second quarter worth $146,000. Nationwide Fund Advisors acquired a new position in shares of American Renal Associates Holdings during the second quarter worth $166,000. Rhumbline Advisers acquired a new position in shares of American Renal Associates Holdings during the second quarter worth $225,000. Finally, Alambic Investment Management L.P. acquired a new position in shares of American Renal Associates Holdings during the second quarter worth $229,000. 85.20% of the stock is owned by institutional investors and hedge funds.

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

5 Day Chart for NYSE:ARA

Receive News & Stock Ratings for American Renal Associates Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc. and related stocks with our FREE daily email newsletter.